NCT04352985 is a clinical trial of Toraymyxin PMX-20R (PMX Cartridge) in Septic Shock, sponsored by Spectral Diagnostics (US) Inc..

Who is sponsoring NCT04352985?

NCT04352985 is sponsored by Spectral Diagnostics (US) Inc..

What drugs are being tested in NCT04352985?

Interventions in NCT04352985: Toraymyxin PMX-20R (PMX Cartridge).

What condition does NCT04352985 study?

NCT04352985 studies Septic Shock, Endotoxemia, COVID, Corona Virus Infection, Sepsis, Severe.

Is NCT04352985 still recruiting?

NCT04352985 is currently no longer available. Last updated 20 September 2021.

Last reviewed 2021-09-20 · How we verify

NCT04352985

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

NO LONGER AVAILABLE Last updated 20 September 2021

What this trial tests

trial testing Toraymyxin PMX-20R (PMX Cartridge) in Septic Shock. No longer available.

Quick facts

Lead sponsor	Spectral Diagnostics (US) Inc.
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	3 locations across United States

Drugs / interventions tested

Toraymyxin PMX-20R (PMX Cartridge)

Conditions studied

Septic Shock — all drugs for Septic Shock →
Endotoxemia — all drugs for Endotoxemia →
COVID — all drugs for COVID →
Corona Virus Infection — all drugs for Corona Virus Infection →

Sponsor

Spectral Diagnostics (US) Inc.

Who can join

18 and older, any sex, with Septic Shock or Endotoxemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review.
Safari S, Salimi A, Zali A, Jahangirifard A, et al · · 2020 · cited 14× · PMID 33134963

Verify or expand the search:

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Other Spectral Diagnostics (US) Inc. trials

Trials by the same sponsor.

NCT03901807 — Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study · NA · active not recruiting
NCT02825329 — Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock · temporarily not available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04352985 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spectral Diagnostics (US) Inc.
Last refreshed: 20 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04352985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing